Prolonged SARS-CoV-2 infection associated with long-term corticosteroid use in a patient with impaired B-cell immunityB 세포 면역이 손상된 환자의 장기간 코르티코스테로이드 사용과 관련된 장기간의 SARS-CoV-2 감염Case Reports Published on 2022-07-012022-09-12 Journal: Journal of infection and chemotherapy : official j [Category] COVID19(2023년), SARS, 진단, [키워드] B-cell Cell-mediated immunity Corticosteroid corticosteroid treatment Corticosteroids COVID-19 dose IgA IgM Immunity Immunocompromised immunocompromised individuals Infection Non-Hodgkin Lymphoma Patient PCR persistence Prolonged reduction Reinfection remained Remdesivir rituximab SARS-CoV-2 SARS-CoV-2 IgG SARS-COV-2 infection Sequencing severe COVID-19 significantly susceptible treat treated Treatment treatment period viral clearance viral shedding viral strain [DOI] 10.1016/j.jiac.2022.02.006 PMC 바로가기 [Article Type] Case Reports
Humoral response to coronavirus disease-19 vaccines is dependent on dosage and timing of rituximab in patients with rheumatoid arthritis코로나바이러스 질병-19 백신에 대한 체액 반응은 류마티스 관절염 환자에서 리툭시맙의 투여량 및 시기에 따라 달라집니다Observational Study Published on 2022-06-282022-09-12 Journal: Rheumatology (Oxford, England) [Category] MERS, 임상, 진단, [키워드] 95% CI age biologic biologic therapies Complete Coronavirus disease-19 COVID-19 COVID-19 vaccination dependent on dosage dose humoral Humoral response investigated methotrexate multivariable logistic regression Netherland Odds ratio Patient patients patients treated positive response RA receiving rheumatoid arthritis rituximab RTX significantly total Ig vaccination Vaccine vaccine response [DOI] 10.1093/rheumatology/keac206 PMC 바로가기 [Article Type] Observational Study
Risk factors of impaired humoral response to COVID-19 vaccination in rituximab-treated patients리툭시맙 치료 환자에서 COVID-19 백신 접종에 대한 체액 반응 장애의 위험 요인Observational Study Published on 2022-06-282022-09-11 Journal: Rheumatology (Oxford, England) [Category] COVID19(2023년), MERS, SARS, 바이오마커, 임상, 진단, 치료기술, [키워드] 95% CI acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Analysis antibody antibody levels Antibody Response B cell B cells CD19 Characteristics chronic inflammatory rheumatic disorder consecutive patient consecutive patients coronavirus coronavirus disease Coronavirus disease 2019 correlated COVID-19 COVID-19 vaccination cut-off value demographics detectable disease Factor humoral Humoral response identify IgG antibody independent Inflammatory monitoring monotherapy MTX multivariate multivariate analyses negative Odds ratio Patient patients produced receiving recruited respiratory rheumatic disease Rheumatic diseases rituximab RTX SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 vaccination seroconversion rate seroconversion rates serology Seropositivity severe acute respiratory syndrome Coronavirus Spike protein Spike proteins therapy two-dose regimen undetectable usual care vaccination were measured [DOI] 10.1093/rheumatology/keab815 PMC 바로가기 [Article Type] Observational Study
Serological Response to BNT162b2 Anti-SARS-CoV-2 Vaccination in Patients with Inflammatory Rheumatic Diseases: Results From the RHEUVAX Cohort염증성 류마티스 질환 환자에서 BNT162b2 Anti-SARS-CoV-2 백신 접종에 대한 혈청학적 반응: RHEUVAX 코호트의 결과Article Published on 2022-06-172022-09-12 Journal: Frontiers in Immunology [Category] MERS, SARS, 진단, [키워드] abatacept age Analysis anti-SARS-CoV-2 vaccine antibody Antibody titer Antibody titers Arthritis Autoimmunity autoinflammatory disease BNT162b2 CCS Community connective tissue connective tissue disease connective tissue disease (CTD) Control Corticosteroid COVID-19 COVID-19 epidemic CTD CTRL disease dose Effective vaccines eight Factor Health profession higher risk identify immune immunological Immunosuppressive medication impair inhibitor IQR jak inhibitors Logistic regression Lower median MMF mycophenolate Necrosis of BNT162b2 Patient patients performed Protein protocol recruited response response to vaccination Result rheumatic and muscoluskeletal disease rheumatic disease rheumatoid arthritis rituximab Sample seroconversion rate severe COVID-19 Specific spike Treatment vaccination vaccine dose Vaccines Vasculitis [DOI] 10.3389/fimmu.2022.901055 PMC 바로가기 [Article Type] Article
New‐onset pemphigus foliaceus following SARS‐CoV‐2 infection and unmasking multiple sclerosis: A case reportCase Reports Published on 2022-06-032024-09-04 Journal: Clinical Case Reports [Category] 대상포진, [키워드] COVID‐19 multiple sclerosis pemphigus pemphigus foliaceus rituximab SARS‐CoV‐2 [DOI] 10.1002/ccr3.5910 PMC 바로가기 [Article Type] Case Reports
Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort studyarticle Published on 2022-06-022024-09-02 Journal: Arthritis Research & Therapy [Category] 대상포진, [키워드] observational study rheumatoid arthritis rituximab Taper [DOI] 10.1186/s13075-022-02826-6 PMC 바로가기 [Article Type] article
Persistent viral shedding of severe acute respiratory syndrome coronavirus 2 after treatment with bendamustine and rituximab: A case report벤다무스틴과 리툭시맙 치료 후 중증급성호흡기증후군 코로나바이러스 2의 지속적인 바이러스 배출: 증례 보고Case Reports Published on 2022-06-012022-09-11 Journal: Journal of infection and chemotherapy : official j [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus Admission Bendamustine Case report Chain Reaction Chemotherapy chemotherapy session chronic disease Chronic diseases condition coronavirus coronavirus disease COVID-19 detectable discharged eight FIVE follicular Follicular lymphoma hospital initiated lymphopenia N501Y nasopharyngeal specimen nine NPs on admission Patient patients persistent persistent infection polymerase chain polymerase chain reaction positive receive receiving respiratory rituximab RNA SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 tested the patient the SARS-CoV-2 therapy Treatment variant Viral viral shedding [DOI] 10.1016/j.jiac.2022.01.014 PMC 바로가기 [Article Type] Case Reports
B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With RituximabB 세포 번호는 리툭시맙으로 치료받은 환자의 SARS-CoV-2 백신 접종 시 체액 및 세포 반응을 예측합니다Article Published on 2022-06-012022-09-12 Journal: Arthritis & rheumatology (Hoboken, N.J.) [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] activated anti-SARS-CoV-2 Antibody Response antigen-specific B cell Autoimmune B cell Biomarker CD4 CD4 T cell CD4/CD8 CD8 T cell Cell cell differentiation cellular complex COVID-19 cytoplasmic Frequency function healthy control higher risk humoral humoral immune response IgG Inflammatory interferon-γ likelihood Lymphocytes Messenger RNA number outcome Patient patients peripheral circulation plasma receiving reduced required response rheumatic disease rheumatoid arthritis rituximab RTX SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine secretion Seroconversion T cell T cell subset Therapies therapy Vaccine Vaccines Vasculitis [DOI] 10.1002/art.42060 PMC 바로가기 [Article Type] Article
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective studyArticle Published on 2022-06-012023-06-11 Journal: Journal of Neurology [Category] B형 간염, Fulltext, [키워드] Cladribine hepatitis B multiple sclerosis Ocrelizumab rituximab vaccination [DOI] 10.1007/s00415-022-11009-x PMC 바로가기
Anti-SARS CoV-2 IgG in COVID-19 Patients with Hematological Diseases: A Single-center, Retrospective Study in Japan혈액 질환이 있는 COVID-19 환자의 Anti-SARS CoV-2 IgG: 일본의 단일 센터, 후향적 연구Article Published on 2022-06-012022-09-11 Journal: Internal medicine (Tokyo, Japan) [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adult COVID-19 patient anti-SARS-CoV-2 anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody antibody caused coronavirus coronavirus disease COVID-19 COVID-19 patient COVID-19 patients COVID-19 severity develop disease Diseases disorders enrolled explain hematological IgG IgG antibodies IgG antibody Immunoglobulin Immunoglobulin G information Japan less objective outcome Patient Receptor-binding domain reported respiratory Result Retrospective study rituximab SARS-CoV-2 SARS-CoV-2 IgG SARS-CoV-2 IgG antibodies Seronegativity Seropositivity severe acute respiratory syndrome Coronavirus significantly single-center Spike protein Spread the receptor-binding domain the spike protein [DOI] 10.2169/internalmedicine.9209-21 PMC 바로가기 [Article Type] Article